drugset / Trial / NCT01462344

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old

NCT01462344

Phase 4 Completed 6250 enrolled GlaxoSmithKline Parexel · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess whether the risk of serious asthma-related events (asthma-related hospitalizations, endotracheal intubations, and deaths) in children 4-11 years old taking inhaled fluticasone propionate/salmeterol combination is the same as those taking inhaled fluticasone propionate alone.

Timeline

Start
2011-11-17
Primary completion
2015-11-01
Completion
2015-11-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Fluticasone propionate Other / unclassified 100 ug Inhaled
Comparator Fluticasone propionate Other / unclassified 250 ug Inhaled
Subject Salmeterol Other / unclassified 50 ug Inhaled

Indications